Vanguard Group Inc Erasca, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,673,900 shares of ERAS stock, worth $20.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,673,900
Previous 13,288,740
4.63%
Holding current value
$20.7 Million
Previous $36.3 Million
12.31%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ERAS
# of Institutions
149Shares Held
227MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$31.6 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$27.4 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$26.4 Million4.58% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$20.4 Million4.12% of portfolio
-
Suvretta Capital Management, LLC New York, NY12.3MShares$20.1 Million1.29% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $199M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...